The 10th MDS Colloquium has been accredited with 9 CME points by the Sächsische Landesärztekammer (SLÄK).
Program
Saturday, 9 November 2019
10th MDS Colloquium
featuring AML & the 7th Annual EMSCO Meeting
| Session 1: | EMSCO trial update |
| 08:30 | Update on ongoing trials Silke Gloaguen, Dresden Fatiha Chermat, Paris |
| 08:50 | EMSCO trials in the pipeline Uwe Platzbecker, Leipzig Lionel Adès, Paris |
| 09:10 | Snapshot of current global clinical research in MDS Pierre Fenaux, Paris |
| 09:30 | Regulatory aspects of clinical trials -> EU 536 Oana Brosteanu, Leipzig |
| Coffee break |
| Session 2: | Pathophysiology & prognosis |
| 10:10 | Stem cell hierarchy in MDS – different than expected? Amit K. Verma, New York |
| 10:30 | Niche and MDS: druggable targets? Daniel Nowak, Mannheim |
| 10:50 | Iron in MDS: fake or fact? Emanuele Angelucci, Cagliari |
| 11:10 | Molecular prognostic markers in MDS and AML Felicitas Thol, Hannover |
| Coffee break |
| Session 3: | Therapy of MDS and AML |
| 11:50 | Standards and perspectives of treatment in lower-risk
MDS – ESA first, EMA second? Uwe Platzbecker, Leipzig |
| 12:10 | HMAs in MDS and AML. Isn’t there any biomarker of
outcome and response? Valeria Santini, Florence |
| 12:30 | Are there any novel concepts of allogeneic transplant
in myelodysplastic syndromes? Guillermo Sanz, Valencia |
| Lunch |
| Session 4: | New targets in MDS and AML |
| 13:50 | How to improve outcome of high-risk MDS and AML in
the elderly? Lionel Adès, Paris |
| 14:10 | IDH1 and 2 revisited – a druggable target with curative potential? |
| 14:30 | Moving from bench to bedside in myeloid
malignancies: the future of AML/MDS? Raphael Itzykson, Paris |
| Coffee break |
| Session 5: | Plenary I |
| 15:10 | Inflammation in bone marrow failure, fact or artefact?
Shahram Kordasti, London |
| 15:35 | Inherited bone marrow failure syndromes – only a
matter of paediatrics?
Marie Sebert, Paris |
| 16:00 | Dyserythropoesis in MDS – causes and consequences Michaela Fontenay, Paris |
| Coffee break |
| Session 6: | Plenary II |
| 16:45 | MDS/MPN, beyond genomic alterations
Eric Solary, Villejuif |
| 17:15 | Presence and future of cellular therapy in hematology
Ulrike Köhl, Leipzig |
| Adjourn |
Speakers
Lionel Adès
Saint Louis Hospital / University of Paris
Hematology Department for the elderly
Paris, France
Emanuele Angelucci
Businco Hospital
Medical Oncology
Cagliari, Italy
Oana Brosteanu
Center for Clinical Trials
University of Leipzig
Leipzig, Germany
Pierre Fenaux
Saint Louis Hospital / University of Paris
Hematology Department for the elderly
Paris, France
Michaela Fontenay
Cochin Hospital / University of Paris
Department of Hematology
Paris, France
Raphael Itzykson
Saint Louis Hospital / University of Paris
Hematology Department for adults
Paris, France
Ulrike Köhl
University Hospital Leipzig
Institute of Clinical Immunology
Leipzig, Germany
Shahram Kordasti
King's College London
Department of Haemato-Oncology
London, United Kingdom
Daniel Nowak
University Hospital Mannheim
Medical Clinic III
Mannheim, Germany
Uwe Platzbecker
University Hospital Leipzig
Medical Clinic and Policlinic I
Leipzig, Germany
Valeria Santini
University Hospital of Florence
Department of Experimental and Clinical Medicine
Firenze, Italy
Guillermo Sanz
University Hospital La Fe
Department of Hematology
Valencia, Spain
Marie Sebert
Saint Louis Hospital / University of Paris
Hematology Department for the elderly
Paris, France
Eric Solary
Gustave Roussy Cancer Institute
Paris, France
Felicitas Thol
Hannover Medical School
Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation
Hannover, Germany
Amit K. Verma
Albert Einstein College of Medicine
Division of Hemato-Oncology
New York, USA
Paresh Vyas
University of Oxford
Radcliffe Department of Medicine
Oxford, UK